CKP Therapeutics (CEO Chan-woong Kim and Jae-ha Lee) is a bio venture that researches and develops compounds for the development of new drugs for drug-resistant cancers in order to achieve its vision of 'extending life expectancy and improving the quality of life of refractory cancer patients'. The company is developing new compounds that directly target cancer stem cells based on research achievements, technology and clinical experience accumulated over 10 years.